Skip to main content

Articles

Page 15 of 39

  1. Aberrant AKT activation contributes to cancer stem cell (CSC) traits in hepatocellular carcinoma (HCC). We previously reported that CD73 activated AKT signaling via the Rap1/P110β cascade. Here, we further exp...

    Authors: Xiao-Lu Ma, Bo Hu, Wei-Guo Tang, Su-Hong Xie, Ning Ren, Lin Guo and Ren-Quan Lu
    Citation: Journal of Hematology & Oncology 2020 13:11
    Content type: Research Published on:

  2. Lung cancer (LC) is the leading cause of cancer-related death worldwide due to its late diagnosis and poor outcomes. As has been found for other types of tumors, there is increasing evidence that myeloid-deriv...

    Authors: Zhenzhen Yang, Jiacheng Guo, Lanling Weng, Wenxue Tang, Shuiling Jin and Wang Ma
    Citation: Journal of Hematology & Oncology 2020 13:10
    Content type: Review Published on:

  3. PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably u...

    Authors: Chenggong Sun, Wenyu Cao, Chunping Qiu, Chengcheng Li, Samina Dongol, Zhiwei Zhang, Ruifen Dong, Kun Song, Xingsheng Yang, Qing Zhang and Beihua Kong
    Citation: Journal of Hematology & Oncology 2020 13:9
    Content type: Research Published on:

  4. Acute myeloid leukemia (AML) is the most common type of adult leukemia. Several studies have demonstrated that oncogenesis in AML is enhanced by kinase signaling pathways such as Src family kinases (SFK) inclu...

    Authors: Ola A. Elgamal, Abeera Mehmood, Jae Yoon Jeon, Bridget Carmichael, Amy Lehman, Shelley J. Orwick, Jean Truxall, Virginia M. Goettl, Ronni Wasmuth, Minh Tran, Shaneice Mitchell, Rosa Lapalombella, Sudharshan Eathiraj, Brian Schwartz, Kimberly Stegmaier, Sharyn D. Baker…
    Citation: Journal of Hematology & Oncology 2020 13:8
    Content type: Research Published on:

  5. Long noncoding RNAs (lncRNAs) are known to regulate tumorigenesis and cancer progression, but their contributions to non-small-cell lung cancer (NSCLC) metastasis remain poorly understood. Our previous and oth...

    Authors: Zhenyao Chen, Xin Chen, Binbin Lu, Yu Gu, Qinnan Chen, Tianyao Lei, Fengqi Nie, Jingyao Gu, Jiali Huang, Chenchen Wei, Ming Sun and Zhaoxia Wang
    Citation: Journal of Hematology & Oncology 2020 13:7
    Content type: Research Published on:

  6. BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases. This phase I study aimed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, ...

    Authors: Xingsheng Hu, Xin Zheng, Sheng Yang, Lin Wang, Xuezhi Hao, Xinge Cui, Lieming Ding, Li Mao, Pei Hu and Yuankai Shi
    Citation: Journal of Hematology & Oncology 2020 13:6
    Content type: Rapid communication Published on:

  7. Long non-coding RNAs (lncRNAs) possess significant regulatory functions in multiple biological and pathological processes, especially in cancer. Dysregulated lncRNAs in hepatocellular carcinoma (HCC) and their...

    Authors: Xueliang Zuo, Zhiqiang Chen, Wen Gao, Yao Zhang, Jinguo Wang, Junfeng Wang, Ming Cao, Juan Cai, Jindao Wu and Xuehao Wang
    Citation: Journal of Hematology & Oncology 2020 13:5
    Content type: Research Published on:

  9. The propensity of the activated neutrophils to form extracellular traps (NETs) is demonstrated in multiple inflammatory conditions. In this study, we investigated the roles of NETs in metastasis of hepatocellu...

    Authors: Lu-Yu Yang, Qin Luo, Lu Lu, Wen-Wei Zhu, Hao-Ting Sun, Ran Wei, Zhi-Fei Lin, Xiang-Yu Wang, Chao-Qun Wang, Ming Lu, Hu-Liang Jia, Jin-Hong Chen, Ju-Bo Zhang and Lun-Xiu Qin
    Citation: Journal of Hematology & Oncology 2020 13:3
    Content type: Research Published on:

  10. Clinically, the median survival in patients with metastatic renal cell carcinoma (RCC) was only 6–12 months and a 5-year survival rate of less than 20%. Therefore, an in-depth study of the molecular mechanisms...

    Authors: Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang…
    Citation: Journal of Hematology & Oncology 2020 13:2
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:110

  11. Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FD...

    Authors: Ahmed Abbasi, Stephen Peeke, Nishi Shah, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Michelly Abreu, Richard Elkind, Karen Fehn, Alyssa de Castro, Yanhua Wang, Olga Derman, Randin Nelson, Joan Uehlinger, Kira Gritsman, R. Alejandro Sica…
    Citation: Journal of Hematology & Oncology 2020 13:1
    Content type: Letter to the Editor Published on:

  12. In 2007, we initiated IMPACT, a precision medicine program for patients referred for participation in early-phase clinical trials. We assessed the correlation of factors, including genomically matched therapy,...

    Authors: Apostolia-Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku, Aung Naing, Siqing Fu, Sarina Piha-Paul, Carrie Cartwright, Russell R. Broaddus, Graciela M. Nogueras Gonzalez, Patrick Hwu and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2019 12:145
    Content type: Research Published on:

  13. Signaling pathways critical for embryonic development re-emerge in adult pancreas during tumorigenesis. Aspartate β-hydroxylase (ASPH) drives embryonic cell motility/invasion in pancreatic development/differen...

    Authors: Kosuke Ogawa, Qiushi Lin, Le Li, Xuewei Bai, Xuesong Chen, Hua Chen, Rui Kong, Yongwei Wang, Hong Zhu, Fuliang He, Qinggang Xu, Lianxin Liu, Min Li, Songhua Zhang, Katsuya Nagaoka, Rolf Carlson…
    Citation: Journal of Hematology & Oncology 2019 12:144
    Content type: Research Published on:

  14. The original article [1] contains several errors.

    Authors: Kai Zhao, Yuxin Zhou, Chen Qiao, Ting Ni, Zhiyu Li, Xiaotang Wang, Qinglong Guo, Na Lu and Libin Wei
    Citation: Journal of Hematology & Oncology 2019 12:143
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2015 8:41

  15. Cancer heterogeneity is regarded as the main reason for the failure of conventional cancer therapy. The ability to reconstruct intra- and interpatient heterogeneity in cancer models is crucial for understandin...

    Authors: Han Fan, Utkan Demirci and Pu Chen
    Citation: Journal of Hematology & Oncology 2019 12:142
    Content type: Review Published on:

  16. Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for the treatment of T cell malig...

    Authors: Lauren C. Fleischer, H. Trent Spencer and Sunil S. Raikar
    Citation: Journal of Hematology & Oncology 2019 12:141
    Content type: Review Published on:

  17. Statistical data on the incidence, mortality, and burden of breast cancer and the relevant risk factors are valuable for policy-making. We aimed to estimate breast cancer incidence, deaths, and disability-adju...

    Authors: Na Li, Yujiao Deng, Linghui Zhou, Tian Tian, Si Yang, Ying Wu, Yi Zheng, Zhen Zhai, Qian Hao, Dingli Song, Dai Zhang, Huafeng Kang and Zhijun Dai
    Citation: Journal of Hematology & Oncology 2019 12:140
    Content type: Research Published on:

  18. Adoptive T cell therapy has achieved dramatic success in a clinic, and the Food and Drug Administration approved two chimeric antigen receptor-engineered T cell (CAR-T) therapies that target hematological canc...

    Authors: Qinghua He, Xianhan Jiang, Xinke Zhou and Jinsheng Weng
    Citation: Journal of Hematology & Oncology 2019 12:139
    Content type: Review Published on:

  19. Endothelial-to-mesenchymal transition (EndoMT) can provide a source of cancer-associated fibroblasts which contribute to desmoplasia of many malignancies including pancreatic ductal adenocarcinoma (PDAC). We i...

    Authors: Chi-Shuan Fan, Li-Li Chen, Tsu-An Hsu, Chia-Chi Chen, Kee Voon Chua, Chung-Pin Li and Tze-Sing Huang
    Citation: Journal of Hematology & Oncology 2019 12:138
    Content type: Research Published on:

  22. METTL3 is an RNA methyltransferase that mediates m6A modification and is implicated in mRNA biogenesis, decay, and translation. However, the biomechanism through which METTL3 regulates MALAT1-miR-1914-3p-YAP axis...

    Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan and Guoming Su
    Citation: Journal of Hematology & Oncology 2019 12:135
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2020 13:106

    The Editor's Note to this article has been published in Journal of Hematology & Oncology 2021 14:32

  25. Src, an oncoprotein that drives progression of head and neck squamous cell carcinoma (HNSCC), is commonly hyperactivated in this disease. Unfortunately, the clinical benefit of targeting Src is significantly d...

    Authors: Liwei Lang, Chloe Shay, Xiangdong Zhao, Yuanping Xiong, Xuli Wang and Yong Teng
    Citation: Journal of Hematology & Oncology 2019 12:132
    Content type: Research Published on:

  26. BCR-ABL1 kinase domain (KD) mutation status is considered to be an important element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do not achieve an optimal response to tyrosine ...

    Authors: Simona Soverini, Elisabetta Abruzzese, Monica Bocchia, Massimiliano Bonifacio, Sara Galimberti, Antonella Gozzini, Alessandra Iurlo, Luigiana Luciano, Patrizia Pregno, Gianantonio Rosti, Giuseppe Saglio, Fabio Stagno, Mario Tiribelli, Paolo Vigneri, Giovanni Barosi and Massimo Breccia
    Citation: Journal of Hematology & Oncology 2019 12:131
    Content type: Review Published on:

  27. Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation se...

    Authors: Hitendra Patel, Ryosuke Okamura, Paul Fanta, Charmi Patel, Richard B. Lanman, Victoria M. Raymond, Shumei Kato and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2019 12:130
    Content type: Short report Published on:

  28. Histone demethylase LSD1 plays key roles during carcinogenesis, targeting LSD1 is becoming an emerging option for the treatment of cancers. Numerous LSD1 inhibitors have been reported to date, some of them suc...

    Authors: Yuan Fang, Guochao Liao and Bin Yu
    Citation: Journal of Hematology & Oncology 2019 12:129
    Content type: Review Published on:

  30. Asparagine-linked (N-linked) glycosylation is ubiquitous and can stabilize immune inhibitory PD-1 protein. Reducing N-linked glycosylation of PD-1 may decrease PD-1 expression and relieve its inhibitory effects o...

    Authors: Xiaojuan Shi, Daiqun Zhang, Feng Li, Zhen Zhang, Shumin Wang, Yujing Xuan, Yu Ping and Yi Zhang
    Citation: Journal of Hematology & Oncology 2019 12:127
    Content type: Letter to the Editor Published on:

  31. Immunotherapy has become an emerging strategy for the treatment of cancer. Immunotherapeutic drugs have been increasing for clinical treatment. Despite significant advances in immunotherapy, the clinical appli...

    Authors: Zhongwei Zhao, Liyun Zheng, Weiqian Chen, Wei Weng, Jingjing Song and Jiansong Ji
    Citation: Journal of Hematology & Oncology 2019 12:126
    Content type: Review Published on:

  32. Immunotherapy is a currently popular treatment strategy for cancer patients. Although recent developments in cancer immunotherapy have had significant clinical impact, only a subset of patients exhibits clinic...

    Authors: Li Yang, Aitian Li, Qingyang Lei and Yi Zhang
    Citation: Journal of Hematology & Oncology 2019 12:125
    Content type: Review Published on:

  33. Human pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint inhibitor (ICPi). While the mechanism is not completely clear, it has been recognized that tumor microenvironment (TME) plays ...

    Authors: Yu Pan, Fengchun Lu, Qinglin Fei, Xingxing Yu, Ping Xiong, Xunbin Yu, Yuan Dang, Zelin Hou, Wenji Lin, Xianchao Lin, Zheyang Zhang, Minggui Pan and Heguang Huang
    Citation: Journal of Hematology & Oncology 2019 12:124
    Content type: Research Published on:

  34. Mitosis is the process whereby an eukaryotic cell divides into two identical copies. Different multiprotein complexes are involved in the fine regulation of cell division, including the mitotic promoting facto...

    Authors: Andrea Ghelli Luserna di Rorà, Giovanni Martinelli and Giorgia Simonetti
    Citation: Journal of Hematology & Oncology 2019 12:123
    Content type: Review Published on:

  35. In the original article [1], the terms ‘osISET’ and ‘ISET’ within the ‘CTC capture’ sub-section of the Materials and Methods section have both been replaced with ‘CTCBIOPSY®’.

    Authors: Xiaobin Lin, Shuyi Wang, Min Sun, Chunxiao Zhang, Chen Wei, Chaogang Yang, Rongzhang Dou, Qing Liu and Bin Xiong
    Citation: Journal of Hematology & Oncology 2019 12:122
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2019 12:20

  36. N6-methyladenosine (m6A) methylation, one of the most common RNA modifications, has been reported to execute important functions that affect normal life activities and diseases. Most studies have suggested tha...

    Authors: Shuai Ma, Chen Chen, Xiang Ji, Jinbo Liu, Quanbo Zhou, Guixian Wang, Weitang Yuan, Quancheng Kan and Zhenqiang Sun
    Citation: Journal of Hematology & Oncology 2019 12:121
    Content type: Review Published on:

  37. The Editor-in-Chief would like to alert readers that the ownership of some of the data presented in this article [1]

    Authors: Benjamin Fourneaux, Aurélien Bourdon, Bérengère Dadone, Carlo Lucchesi, Scott R. Daigle, Elodie Richard, Audrey Laroche-Clary, François Le Loarer and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2019 12:116
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2019 12:11

  38. Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and m...

    Authors: Chao Wu, Lina Zhang, Qierra R. Brockman, Fenghuang Zhan and Lijuan Chen
    Citation: Journal of Hematology & Oncology 2019 12:120
    Content type: Review Published on:

  39. Double-hit lymphoma (DHL) is among the most aggressive and chemoresistant lymphoma subtypes. DHLs carry genomic abnormalities in MYC, BCL2, and/or BCL6 oncogenes. Due to the simultaneous overexpression of thes...

    Authors: Yuanhui Liu, Nancy G. Azizian, Yaling Dou, Lan V. Pham and Yulin Li
    Citation: Journal of Hematology & Oncology 2019 12:119
    Content type: Rapid communication Published on:

  41. The original article [1] contains an error in authorship whereby author, Robert Weinkove’s name is mistakenly inverted. The configuration noted in this Correction article should be considered instead along wit...

    Authors: Jianyu Weng, Peilong Lai, Le Qin, Yunxin Lai, Zhiwu Jiang, Chenwei Luo, Xin Huang, Suijing Wu, Dan Shao, Chengxin Deng, Lisi Huang, Zesheng Lu, Maohua Zhou, Lingji Zeng, Dongmei Chen, Yulian Wang…
    Citation: Journal of Hematology & Oncology 2019 12:117
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2018 11:25

  43. Clonal evolution of chronic lymphocytic leukemia (CLL) often follows chemotherapy and is associated with adverse outcome, but also occurs in untreated patients, in which case its predictive role is debated. We...

    Authors: Alice Ramassone, Andrea D’Argenio, Angelo Veronese, Alessio Basti, Shimaa Hassan AbdelAziz Soliman, Stefano Volinia, Cristian Bassi, Sara Pagotto, Manuela Ferracin, Laura Lupini, Elena Saccenti, Veronica Balatti, Felice Pepe, Laura Z. Rassenti, Idanna Innocenti, Francesco Autore…
    Citation: Journal of Hematology & Oncology 2019 12:114
    Content type: Letter to the Editor Published on:

  45. Increased liver stiffness exerts a detrimental role in driving hepatocellular carcinoma (HCC) malignancy and progression, and indicates a high risk of unfavorable outcomes. However, it remains largely unknown ...

    Authors: Yinying Dong, Qiongdan Zheng, Zhiming Wang, Xiahui Lin, Yang You, Sifan Wu, Yaohui Wang, Chao Hu, Xiaoying Xie, Jie Chen, Dongmei Gao, Yan Zhao, Weizhong Wu, Yinkun Liu, Zhenggang Ren, Rongxin Chen…
    Citation: Journal of Hematology & Oncology 2019 12:112
    Content type: Research Published on:

  46. Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics in a significant part of patients. Immunotherapeutical agents represent an emerging option for breast cancer treatm...

    Authors: E. Krasniqi, G. Barchiesi, L. Pizzuti, M. Mazzotta, A. Venuti, M. Maugeri-Saccà, G. Sanguineti, G. Massimiani, D. Sergi, S. Carpano, P. Marchetti, S. Tomao, T. Gamucci, R. De Maria, F. Tomao, C. Natoli…
    Citation: Journal of Hematology & Oncology 2019 12:111
    Content type: Review Published on:

  47. Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients need at least one systemic therapy at different phases of their treatment for HCC. S...

    Authors: Xiao-Dong Zhu and Hui-Chuan Sun
    Citation: Journal of Hematology & Oncology 2019 12:110
    Content type: Review Published on:

  48. The original article [1] contained an error in Fig. 7c whereby the same flow image was accidentally misused for the second and fourth group.

    Authors: Lufeng Zheng, Qianqian Guo, Chenxi Xiang, Shijia Liu, Yuzhang Jiang, Lanlan Gao, Haiwei Ni, Ting Wang, Qiong Zhao, Hai Liu, Yingying Xing, Yaohui Wang, Xiaoman Li and Tao Xi
    Citation: Journal of Hematology & Oncology 2019 12:109
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2019 12:23

  49. Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies. Its prognostic value in acute lymphoblastic leuke...

    Authors: Jiří Pavlů, Myriam Labopin, Riitta Niittyvuopio, Gerard Socié, Ibrahim Yakoub-Agha, Depei Wu, Peter Remenyi, Jakob Passweg, Dietrich W. Beelen, Mahmoud Aljurf, Nicolaus Kröger, Hélène Labussière-Wallet, Zinaida Perić, Sebastian Giebel, Arnon Nagler and Mohamad Mohty
    Citation: Journal of Hematology & Oncology 2019 12:108
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us